Affinity Asset Advisors LLC Lowers Stock Holdings in Savara Inc. $SVRA

Affinity Asset Advisors LLC trimmed its position in shares of Savara Inc. (NASDAQ:SVRA) by 10.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,512,153 shares of the company’s stock after selling 285,000 shares during the quarter. Affinity Asset Advisors LLC’s holdings in Savara were worth $13,716,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Polar Capital Holdings Plc purchased a new position in shares of Savara in the fourth quarter valued at approximately $50,086,000. RTW Investments LP acquired a new stake in Savara during the 4th quarter worth approximately $35,893,000. VR Adviser LLC boosted its position in Savara by 172.7% in the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock valued at $20,256,000 after buying an additional 5,626,624 shares during the period. Marshall Wace LLP purchased a new position in Savara in the 4th quarter valued at approximately $27,496,000. Finally, Spruce Street Capital LP purchased a new position in Savara in the fourth quarter valued at $14,539,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Stock Down 4.2%

SVRA stock opened at $5.51 on Friday. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. Savara Inc. has a twelve month low of $2.43 and a twelve month high of $7.01. The company’s 50 day moving average is $5.53 and its two-hundred day moving average is $5.52. The stock has a market cap of $1.13 billion, a P/E ratio of -9.84 and a beta of 0.24.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Research analysts expect that Savara Inc. will post -0.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on SVRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, Oppenheimer began coverage on shares of Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.